AN INVESTIGATION ABOUT WEIGHT GAIN WITH TREATMENT OF IRON DEFICIENCY ANEMIA: CHANGES OF GHRELIN AND HEPCIDIN LEVELS WITH TREATMENT

EHA Library, Birgul Onec, 180941

SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING

EHA Library, Tomas Stopka, 180942

WHOLE GENOME MBD-SEQ REVEALS DIFFERENT CPG METHYLATION PATTERNS IN AZACYTIDINE-TREATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) PATIENTS

EHA Library, Pier Paolo Leoncini, 180943

RESPONSE MONITORING IN MDS WITH DEL(5Q) USING DIFFERENT FLOW CYTOMETRIC (FCM)-SCORES IN COMPARISON TO CYTOGENETICS – AN ELNET IMDS-FLOW EXPERIENCE

EHA Library, Uta OELSCHLAEGEL, 180944

EVALUATION OF MUTATIONS AT RELAPSE IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Monica Cabrero, 180945

RIGOSERTIB COMBINED WITH AZACITIDINE EPIGENETICALLY MODULATES CHROMATIN AND HEMATOPOIETIC STEM CELL POPULATIONS IN THE MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Lewis Silverman, 180946

UNEXPLAINED CYTOPENIAS IN HOSPITAL : INDICATIONS AND BENEFITS OF NEXT-GENERATION SEQUENCING

EHA Library, David Beauvais, 180947

RESISTANCE TO AZACITIDINE IS DETERMINED AT CELLULAR LEVEL BY LOWER EXPRESSION OF NUCLEOSIDE ACTIVATING ENZYMES UCK1 AND UCK2

EHA Library, Valeria Santini, 180949

FAMILIAL TIN2 N-TERMINAL LOSS OF FUNCTION MUTATION IN TELOMERE SYNDROME

EHA Library, Danika Di Giacomo, 180950

FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Toshio Asayama, 180951

PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE LOCI OF GENE VARIANCES

EHA Library, Temenuzhka Boneva, 180952

SUPPRESSION OF DNA METHYLTRANSFERASE ENZYMES BY A NOVEL HYPOMETHYLATING AGENT, SGI-1027, IN AZACITIDINE- AND DECITABINE-RESISTANT CELL LINES

EHA Library, Eun-Hye HUR, 180953

MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Mathieu Meunier, 180954

EVALUATING ERYTHROBLAST PAS POSITIVITY IN THE DIAGNOSTIC APPROACH OF MYELODYSPLASTIC SYNDROME

EHA Library, Rosangela Invernizzi, 180955

A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Uwe Platzbecker, 180956

PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY.

EHA Library, Felix Lopez Cadenas, 180957

MYELODYSPLASIA-RELATED MORTALITY REMAINS THE MAIN CAUSE OF DEATH ALONG DIFFERENT GROUPS OF RISKS: AN ANALYSIS FROM MDS ARGENTINEAN STUDY GROUP

EHA Library, Alicia Enrico, 180958

PROSPECTIVE STUDY OF FLOW CYTOMETRY OF BONE MARROW IN 105 CONSECUTIVE PATIENTS WITH CYTOPENIA AND SUSPICION OF MYELODYSPLASTIC SYNDROME: STRONG CORRELATION WITH RISK OF AML-EVOLUTION AND SURVIVAL

EHA Library, Fernando Marco De Lucas, 180959

ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

EHA Library, Jill Bell, 180960

INTRAVENOUS IMMUNOGLOBULIN IS AN EFFECTIVE TREATMENT FOR CYTOPENIAS ASSOCIATED TO CIRCULATING T-CELL CLONES IN MYELODYSPLASTIC SYNDROMES

EHA Library, Lewis Silverman, 180961

DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES

EHA Library, Fabio Efficace, 180962

PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF SIGNIFICANT MARROW FIBROSIS IN COMBINATION WITH P53 OVER-EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: A SINGLE CENTRE STUDY

EHA Library, Emma Groarke, 180963

FACS PURIFICATION OF BLAST CELLS IN MDS IMPROVES THE FISH DETECTION RATE FOR DEL(5Q) AND DEL(20Q), BUT NOT FOR DEL(7Q) OR T8

EHA Library, Marta Pereira, 180964

COUNTING BONE MARROW BLASTS AS A PERCENTAGE OF NON-ERYTHROID CELLS PROVIDES SUPERIOR RISK STRATIFICATION FOR MDS PATIENTS WITH ERYTHROID PREDOMINANCE

EHA Library, Aining Sun, 180965

SUCCESSFUL TREATMENT WITH DANAZOL FOR MYELODYSPLASTIC SYNDROMES AND APLASTIC ANEMIA REFRACTORY OR INELIGIBLE TO STANDARD THERAPY

EHA Library, Anna Maria Pelizzari, 180966

SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

EHA Library, Jill Bell, 180967

DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Mohammad Azab, 180968

FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER- RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE.

EHA Library, Krzysztof Madry, 180969

OVERALL SURVIVAL, INITIAL TREATMENT AND TREATMENT DURATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME, A DETAILED POPULATION BASED STUDY

EHA Library, Hanne Rozema, 180970

DANAZOL TREATMENT FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A REAL LIFE EXPERIENCE

EHA Library, Emanuele Ravano, 180971

TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY

EHA Library, Jill Bell, 180972

APPRECI8: A PIPELINE FOR PRECISE VARIANT CALLING INTEGRATING 8 TOOLS

EHA Library, Sarah Sandmann, 180973

COMPARISON OF ADMINISTRATION OF HYPOMETHYLATING AGENTS WITH EFFICIENCY OF ALLOGENEIC SCT IN ELDERLY PATIENTS WITH ADVANCED MDS

EHA Library, Jaroslav Cermak, 180974

A MULTICENTER, OPEN-LABEL, PHASE I CLINICAL STUDY: SAFETY, EFFICACY, AND PHARMACOKINETICS OF ORAL RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES

EHA Library, Kenichi Ishizawa, 180975

NON-OVERLAPPING PROMOTER AND SUPERENHANCER DRIVEN PROCESSES SUPPORT MYELOMA CELL GROWTH AND SURVIVAL VIA DISTINCT REGULATORY AXES

EHA Library, Mariateresa Fulciniti, 180976

ANALYSIS OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA HIGHLIGHTS NOVEL CANDIDATE PROGNOSTIC MARKERS AND DISEASE SUBGROUPS

EHA Library, Niccolò Bolli, 180977

A NOVEL METHOD FOR GENOME-WIDE COPY NUMBER ASSESSMENT FROM TARGETED SEQUENCING DATA AND CLINICAL APPLICATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Georgie Ryland, 180978

THE MULTIPLE MYELOMA GENOME PROJECT: DEVELOPMENT OF A MOLECULAR SEGMENTATION STRATEGY FOR RISK STRATIFICATION OF MULTIPLE MYELOMA

EHA Library, Gareth Morgan, 180979

ALVOCIDIB SYNERGIZES WITH VENETOCLAX IN PRECLINICAL MODELS OF MULTIPLE MYELOMA

EHA Library, Steven Warner, 180980

NOVEL COMPOUND, OSSL_325096, INDUCES APOPTOSIS IN MULTIPLE MYELOMA CELLS THROUGH VCP INHIBITION

EHA Library, Nao Nishimura, 180981

A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA

EHA Library, Mehmet Samur, 180982

DYNAMIC IMMUNOHISTOCHEMICAL EVALUATION OF MARROW MICROENVIRONMENT MODIFICATIONS IN PATIENTS WITH SMOLDERING MYELOMA

EHA Library, Alberto Mussetti, 180983

IMMUNE CELL PROFILING IN BONE MARROW OF MYELOMA PATIENTS POST AUTOLOGUS STEM CELL TRANSPLANT SHOWS PRESENCE OF CYTOTOXIC CD4 AND CD8 CELLS, WITH PROMINENT LAG-3 EXPRESSION AND OTHER CHECKPOINT MARKERS

EHA Library, Nouf Alrasheed, 180984

INHIBITION OF EXTRACELLULAR VESICLE SECRETION INDUCES APOPTOSIS OF BONE MARROW STROMAL CELLS: TOWARDS SOIL-TARGETED THERAPY IN MULTIPLE MYELOMA

EHA Library, Tomohiro UMEZU, 180985

SINGLE-NUCLEOTIDE POLYMORPHISM IN THE PBK GENE IS CLOSELY ASSOCIATED WITH MYELOMA CELL PROLIFERATION.

EHA Library, Ichiro Hanamura, 180986

THE HISTONE METHYLTRANSFERASES G9A/GLP REPRESENT NEW PROMISING TARGETS FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Eva De Smedt, 180987

CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPUTIC OPPORTUNITIES

EHA Library, Frances Seymour, 180988

P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE MYELOMA

EHA Library, Yohei Arihara, 180989

TUMOR MICROENVIRONMET TRANSFORMATION FROM MGUS TO MYELOMA IS ASSOCIATED WITH PRO-TUMORAL ACTIVATION OF MESENCHYMAL STROMAL CELLS (MSC)

EHA Library, Cesarina Giallongo, 180990

LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NEXT GENERATION FLOW SHOW PREDOMINANTLY CURED VS MGUS-LIKE MINIMAL RESIDUAL DISEASE PATTERNS: A STUDY OF THE GTMM-TUSCAN GROUP FOR MULTIPLE MYELOMA

EHA Library, Alessandro Gozzetti, 180991

THE NOTCH PATHWAY IN THE INTERPLAY BETWEEN MYELOMA CELLS AND ENDOTHELIUM IN THE BONE MARROW NICHE

EHA Library, Maria Teresa Palano, 180992

MIR-101-3P REGULATES BONE MARROW STROMA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA CELLS BY TARGETING SURVIVIN AND MODULATING CELL-CELL ADHESION

EHA Library, Jahangir Abdi, 180993

ARQ-197, A SMALL-MOLECULE INHIBITOR OF C-MET, REDUCES TUMOUR BURDEN AND PREVENTS TUMOUR-ASSOCIATED BONE DISEASE IN A MURINE MODEL OF MYELOMA

EHA Library, Andrew Chantry, 180994

THE GENETIC LANDSCAPE OF THE MURINE 5T MODELS FOR MULTIPLE MYELOMA

EHA Library, Ken Maes, 180996

CHARACTERIZING THE CONTRIBUTION OF BONE MARROW STROMA-DERIVED IL-6 TO MYELOMA GROWTH AND RESISTANCE

EHA Library, Tamas Csikos, 180997

THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VITRO AND IN VIVO MODELS OF MULTIPLE MYELOMA

EHA Library, Teresa Paíno, 180998

EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA.

EHA Library, Nicola Giuliani, 180999

TRIM33 IS A POTENTIAL TUMOR SUPPRESSOR IN MULTIPLE MYELOMA

EHA Library, Cliona , 181000

LONG NON-CODING RNAS EXPRESSION HETEROGENEITY AND FUNCTIONAL INVOLVEMENT IN MULTIPLE MYELOMA

EHA Library, Arantxa Carrasco, 181001

ROLE OF EPHA3 IN MULTIPLE MYELOMA: A PERSPECTIVE FOR A NOVEL TARGET THERAPY?

EHA Library, FRANCESCO LA ROCCA, 181002

PROGNOSTIC SIGNIFICANCE OF AMP1Q21 IN MULTIPLE MYELOMA

EHA Library, Tatiana Abramova, 181003

ADAPTIVE IMMUNE RESPONSE IN PLASMA CELL DYSCRASIAS: IMMUNE PROFILING AND DETERMINATION OF CIRCULATING B CELL LEVELS AS A SURROGATE ASSAY FOR BONE MARROW TESTING

EHA Library, Stephen Drain, 181004

NOVEL MONOCLONAL ANTIBODY THERAPY TARGETING CD26 IN MULTIPLE MYELOMA

EHA Library, Hiroko Nishida, 181005

KYNURENINE INHIBITS T-CELLS THROUGH THE ARYL HYDROCARBON RECEPTOR AT IDO-POSITIVE TUMOR MICROENVIRONMENT

EHA Library, Soranobu Ninomiya, 181006

THE ANTI-MYELOMA ACTIVITY OF PERK KINASE INHIBITOR IN TARGETING MORE THAN 50 UPR-RELATED GENES INVOLVED IN THE PROLIFERATION OF MM CELLS

EHA Library, Tina Bagratuni, 181007

ENVIRONMENTAL CONTROL OF PLASMA CELL FITNESS IN MULTIPLE MYELOMA: MALIGNANT CO-OPTATION OF ARGININE AS NOVEL IMMUNO-METABOLIC CHECKPOINT

EHA Library, Alessandra Romano, 181008

ESTIMATED GLOMERULAR FILTRATION (EGFR) CALCULATED BY CKD-EPI EQUATION COMBINED WITH THE INTERNATIONAL STAGING SYSTEM PROVIDES A POWERFUL PROGNOSTIC MODEL FOR EARLY MORTALITY IN MYELOMA PATIENTS

EHA Library, Eirini Katodritou, 181009

ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND CLONOGENIC TUMOR CELLS

EHA Library, Alejandra Leivas, 181010

UNMASKING THE RETROTRANSPOSON-ORCHESTRATED PRODUCTION OF SOLUBLE RANKL IN MULTIPLE MYELOMA CELLS

EHA Library, Spyros Papamichos, 181011

THE RATIO OF PATHOLOGICAL PLASMOCYTES, ASSESSED BY 8-COLOR FLOW CYTOMETRY, PREDICTS OF RISK OF EVOLUTION IN MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AND SMOULDERING MULTIPLE MYELOMA.

EHA Library, Ludovic LHERMITTE, 181012

ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION.

EHA Library, Alberto Horenstein, 181013

TREATMENT OPTIMIZATION FOR MULTIPLE MYELOMA: SCHEDULE-DEPENDENT SYNERGISTIC CYTOTOXICITY OF POMALIDOMIDE AND CARFILZOMIB ON AN IN VITRO AND EX-VIVO MODEL

EHA Library, Enrica Borsi, 181014

IMPACT OF POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) MAINTENANCE THERAPY ON OUTCOMES IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING THE LARGE PROSPECTIVE COMMUNITY-BASED CONNECT® MM REGISTRY

EHA Library, Sundar Jagannath, 181015

DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRETREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Prashant Kapoor, 181016

IMPACT OF METFORMIN USE IN THE OUTCOMES OF MULTIPLE MYELOMA PATIENTS POST STEM CELL TRANSPLANT.

EHA Library, Narjust Duma, 181017

COMPARING WHOLE BODY MRI WITH PET-CT IMAGING AT DIAGNOSIS OF MYELOMA

EHA Library, Ieuan WALKER, 181018

PERSISTENCE OF MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY CAN HINDER RECOVERY OF ORGAN DAMAGE IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Paolo Milani, 181019

RATES OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CARFILZOMIB VS COMPARATORS IN PIVOTAL PHASE 3 TRIALS

EHA Library, Ruben Niesvizky, 181020

EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA IS A POOR PROGNOSTIC MARKER FOR OVERALL SURVIVAL AND IS DIFFICULT TO PREDICT AT DIAGNOSIS OR DURING INDUCTION TREATMENT.

EHA Library, Ieuan WALKER, 181021

PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTRÖM MACROGLOBULINEMIA (WM)

EHA Library, Judith Trotman, 181022

INCIDENCE AND RISK FACTORS OF CARDIOVASCULAR ADVERSE EVENTS IN A LARGE POPULATION OF NEWLY-DIAGNOSED, TRANSPLANT INELIGIBLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB.

EHA Library, Sara Bringhen, 181023

POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS

EHA Library, David S. Siegel, 181024

“REAL WORLD” DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 181025

EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY IN A LARGE COHORT OF PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB

EHA Library, Barbara Gamberi, 181026

NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE OF MULTIPLE MYELOMA PATIENTS

EHA Library, Nicole Skoetz, 181027

WT1 HETEROCLITIC EPITOPE IMMUNIZATION FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM)

EHA Library, Guenther KOEHNE, 181028

ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH PROGRESSIVE DISEASE AT TIME OF FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION: PREDICTORS OF PROGRESSIVE DISEASE AND FACTORS AFFECTING SURVIVAL

EHA Library, Joanna Blocka, 181029

SEVERE INFECTIONS IMPACTS OVERALL SURVIVAL IN ACTIVE MULTIPLE MYELOMA PATIENTS

EHA Library, Gregorio Barilà, 181030

EVALUATION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES OF MULTIPLE MYELOMA IN THE REAL-WORLD SETTING IN THE UNITED STATES

EHA Library, Clara Chen, 181031

LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

EHA Library, Katrin Kupas, 181032

HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP

EHA Library, Iwona Hus, 181033

HIGH CUT OFF HEMODIALYSIS FOR RENAL RECOVERY IN PATIENTS WITH MULTIPLE MYELOMA: FIVE YEARS OF EXPERIENCE

EHA Library, Ana BERNI WENNEKERS, 181034

IMPACT OF IMMUNOPARESIS IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS

EHA Library, Luis Gerardo Rodríguez-Lobato, 181035

TREATMENT PATTERNS AND DURATION OF TREATMENT IN JAPANESE MULTIPLE MYELOMA PATIENTS RECEIVING SECOND LINE THERAPY WITH NOVEL AGENTS

EHA Library, Gyungjin Jun, 181036

ROLE OF HEAVY/LIGHT CHAIN RATIO IN MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST LINE THERAPY

EHA Library, Fiorella D'auria, 181037

REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE POLISH MYELOMA GROUP.

EHA Library, Krzysztof Jamroziak, 181038

REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE

EHA Library, Alonso Fernandez, 181039

FRAILTY AND MORTALITY IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Natalia Schutz, 181040

PROGNOSIS OF AL AMYLOIDOSIS WITH KIDNEY INJURY

EHA Library, Talbot Alexis, 181041

REAL-WORLD DATA ON THE TREATMENT OF RELAPSED/REFRACTORY MYELOMA WITH LENALIDOMIDE AND DEXAMETHASONE IN 2ND LINE (LEGEND STUDY): THE PROGNOSTIC SIGNIFICANCE OF BIOCHEMICAL VS. CLINICAL RELAPSE

EHA Library, Eirini Katodritou, 181042